Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence of Replication of Human Herpes Virus 6 (HHV6) in Blood and Skin During Exanthemia, in Patients With Hemopathy. Is There a Correlation With the Etiology of the Exanthema? (REPLIPO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03102905
Recruitment Status : Unknown
Verified March 2017 by Centre Hospitalier Universitaire, Amiens.
Recruitment status was:  Recruiting
First Posted : April 6, 2017
Last Update Posted : April 6, 2017
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire, Amiens

Brief Summary:
To look for the replication of HHV6 by PCR in the skin, in these patients with haemopathies presenting an exanthema. This will make it possible to evaluate the prevalence of the positivity of this PCR in the skin. Then the investigator can investigate whether there is an association between the positivity of HHV6 PCR in the blood and / or skin and the viral etiology of the exanthema. If this association exists, it will make it possible to improve the diagnosis in the context of the exanthema and thus to improve the therapeutic management of these patients.

Condition or disease Intervention/treatment
HHV6 Exanthema Hemopathy Other: Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 45 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Prevalence of Replication of Human Herpes Virus 6 (HHV6) in Blood and Skin During Exanthemia, in Patients With Hemopathy. Is There a Correlation With the Etiology of the Exanthema?
Actual Study Start Date : December 13, 2016
Estimated Primary Completion Date : June 13, 2017
Estimated Study Completion Date : June 13, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Rashes


Intervention Details:
  • Other: Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied.
    To evaluate the prevalence of the positivity of HHV6 PCR in the skin, during the exanthema in patients hospitalized for haemopathy.


Primary Outcome Measures :
  1. Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied. [ Time Frame: 1 day ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Any patient hospitalized in the Clinical Hematology and Cellular Therapy department of the CHU Amiens-Picardie between 01/01/2011 and 31/01/2016
Criteria

Inclusion Criteria:

  • Supported for any type of hemopathy.
  • Allograft, autografted or ungrafted haematopoietic stem cells
  • Having presented an exanthema during hospitalization, for which a cutaneous biopsy had been performed
  • Having had a blood test of the HHV6 virus by PCR at least within the previous 40 days or following the rash.
  • Age greater than or equal to 18 years
  • Patient informed of the protocol by post, not having refused within one month of sending the said courier.

Exclusion Criteria:

  • Patient who refused the search.
  • Patient whose HHV6 PCR in the blood was carried out at a distance of more than 40 days from the skin biopsy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03102905


Contacts
Layout table for location contacts
Contact: Guillaume CHABY, Dr +33322455846 chaby.guillaume@chu-amiens.fr

Locations
Layout table for location information
France
CHU Amiens Picardie Recruiting
Amiens, Picardie, France, 80054
Contact: Guillaume CHABY, Dr    +33322455846    chaby.guillaume@chu-amiens.fr   
Sponsors and Collaborators
Centre Hospitalier Universitaire, Amiens
Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire, Amiens
ClinicalTrials.gov Identifier: NCT03102905    
Other Study ID Numbers: PI2016_843_0017
First Posted: April 6, 2017    Key Record Dates
Last Update Posted: April 6, 2017
Last Verified: March 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Exanthema
Skin Diseases